Retraction Note to: Different Aspects of Sartan + Calcium Antagonist Association Compared to the Single Therapy on Inflammation and Metabolic Parameters in Hypertensive Patients (Inflammation, 37, 1, 2014 [154-162], Doi 10.1007/s10753-013-9724-x);Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients

Inflammation

Volumn 37, Issue 1, 2014, Pages 154-162

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   Carbone, Anna ^c   Querci, Fabrizio ^d   Fogari, Elena ^a   D'Angelo, Angela ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Hospital Center of Diabetes   (Italy)

^d Ospedale Pesenti Fenaroli   (Italy)

Author keywords

adiponectin; amlodipine; high sensitivity C reactive protein; monocyte chemoattractant protein 1; olmesartan

Indexed keywords

ADIPONECTIN; AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; C REACTIVE PROTEIN; GLUCOSE; INSULIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; TETRAZOLES;

EID: 84900351465     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0223-0     Document Type: Erratum

References (47)

1. Grundy, S.M., J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr., J.A. Spertus, F. Costa, American Heart Association, and National Heart, Lung, and Blood Institute. 2005. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112(17): 2735-2752. (Pubitemid 41532612)
2. WRITING GROUP MEMBERS, D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, G. De Simone, T.B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P.M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M.M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V.L. Roger, W. Rosamond, R. Sacco, P. Sorlie, V.L. Roger, T. Thom, S. Wasserthiel-Smoller, N.D. Wong, J. Wylie-Rosett, and American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2010. Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 121(7): e46-e215.
3. Gradman, A.H., J.N. Basile, B.L. Carter, G.L. Bakris, and American Society of Hypertension Writing Group. 2010. Combination therapy in hypertension. Journal of the American Society of Hypertension 4(1): 42-50.
4. Wald, D.S., M. Law, J.K. Morris, J.P. Bestwick, and N.J. Wald. 2009. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. American Journal of Medicine 122(3): 290-300.
5. de la Sierra, A., and M. Volpe. 2013. Olmesartan-based therapies: An effective way to improve blood pressure control and cardiovascular protection. Journal of Hypertension 31(1): S13-S17.
6. Lichtenstein, A.H., L.J. Appel, M. Brands, M. Carnethon, S. Daniels, H.A. Franch, B. Franklin, P. Kris-Etherton, W.S. Harris, B. Howard, N. Karanja, M. Lefevre, L. Rudel, F. Sacks, L. Van Horn, M. Winston, and J. Wylie-Rosett. 2006. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 2186-2191. (Pubitemid 44465710)
7. Epstein, B.J., K. Vogel, and B.F. Palmer. 2007. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67(9): 1309-1327. (Pubitemid 46879096)
8. Oparil, S., and M. Weber. 2009. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: An emerging strategy in hypertension therapy. Postgraduate Medicine 121(2): 25-39.
9. Gradman, A.H., J.N. Basile, B.L. Carter, G.L. Bakris, B.J. Materson, H.R. Black, J.L. Izzo Jr., S. Oparil, and M.A. Weber. 2010. Combination therapy in hypertension. Journal of the American Society of Hypertension 4(2): 90-98.
10. Nesbitt, S.D., A. Shojaee, J.F. Maa, and M.R. Weir. 2013. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). Journal of Human Hypertension 27(7): 445-452.
11. European Diabetes Policy Group. 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 16: 716-730.
12. Heding, L.G. 1972. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260-266.
13. Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419. (Pubitemid 15018832)
14. Klose, S., and K. Borner. 1978. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). Journal of Clinical Chemistry and Clinical Biochemistry 15: 121-130. (Pubitemid 8061822)
15. Wahlefeld, A.W. 1974. Triglycerides determination after enzymatic hydrolysis. In Methods of enzymatic analysis, 2nd ed, ed. H.U. Bermeyer, 18-31. New York: Academic.
16. Havel, R.J., H.A. Edr, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation 34: 1345-1353.
17. Friedewald, W.T., R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499-502.
18. Yamauchi, T., J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, and T. Kadowaki. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7: 941-946. (Pubitemid 32756432)
19. Rifai, N., R.P. Tracy, and P.M. Ridker. 1999. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 45(12): 2136-2141.
20. Hasegawa, M., S. Sato, and K. Takehara. 1999. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1α) in patients with systemic sclerosis MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clinical and Experimental Immunology 117: 159-165. (Pubitemid 29292792)
21. De Fronzo, R.A., J.A. Tobin, and B. Andres. 1979. Glucose clamp technique, a method for quantifying insulin secretion and resistance. American Journal of Physiology 237: 214-223.
22. Ferrannini, E., G. Buzzigoli, R. Bonadonna, M.A. Giorico, M. Oleggini, L. Graziadei, R. Pedrinelli, L. Brandi, and S. Bevilacqua. 1987. Insulin resistance in essential hypertension. New England Journal of Medicine 317(6): 350-357. (Pubitemid 17118813)
23. Winer, B.J. 1971. Statistical principles in experimental design, 2nd ed. New York: McGraw-Hill.
24. Fogari, R., A. Zoppi, A. Mugellini, P. Preti, T. Perrone, P. Maffioli, and G. Derosa. 2012. Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. Expert Opinion on Pharmacotherapy 13(5): 629-636.
25. Derosa, G., P. Maffioli, S.A. Salvadeo, I. Ferrari, A. Gravina, R. Mereu, I. Palumbo, E. Fogari, A. D'Angelo, and A.F. Cicero. 2010. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertension Research 33(8): 790-795.
26. Fogari, R., G. Malamani, L. Corradi, A. Mugellini, P. Preti, A. Zoppi, and G. Derosa. 2010. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Advances in Therapy 27(1): 48-55.
27. Fogari, R., G. Derosa, A. Zoppi, A. Rinaldi, P. Preti, P. Lazzari, and A. Mugellini. 2008. Effects of manidipine/delapril versus olmesartan/ hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertension Research 31(1): 43-50. (Pubitemid 351325614)
28. Fogari, R., G. Derosa, A. Zoppi, P. Lazzari, L. Corradi, P. Preti, and A. Mugellini. 2008. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Internal Medicine 47(5): 361-366. (Pubitemid 351663685)
29. Fogari, R., A. Zoppi, A. Mugellini, P. Preti, M. Destro, A. Rinaldi, and G. Derosa. 2006. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Advances in Therapy 23(5): 680-695. (Pubitemid 44955847)
30. Fogari, R., A. Zoppi, A. Mugellini, P. Maffioli, P. Preti, and G. Derosa. 2012. Effects of valsartan or ramipril addition to amlodipine/ hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opinion on Pharmacotherapy 13(8): 1091-1099.
31. Fogari, R., P. Maffioli, A. Mugellini, A. Zoppi, P. Lazzari, and G. Derosa. 2012. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. European Journal of Gastroenterology and Hepatology 24(2): 164-171.
32. Fogari, R., A. Zoppi, P. Maffioli, P. Lazzari, A. Mugellini, and G. Derosa. 2011. Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opinion on Pharmacotherapy 12(16): 2441-2448.
33. Fogari, R., A. Mugellini, M. Destro, L. Corradi, P. Lazzari, A. Zoppi, P. Preti, and G. Derosa. 2012. Losartan and amlodipine on myocardial structure and function: A prospective, randomized, clinical trial. Diabetic Medicine 29(1): 24-31.
34. Fogari, R., A. Zoppi, A. Mugellini, P. Maffioli, P. Lazzari, C. Monti, and G. Derosa. 2011. Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: A three-way crossover study. Expert Opinion on Pharmacotherapy 12(9): 1351-1358.
35. Derosa, G., and P. Maffioli. 2011. Drug safety evaluation of amlodipine. Expert Opinion on Drug Safety 10(5): 795-804.
36. Chrysant, S.G., M. Melino, S. Karki, J. Lee, and R. Heyrman. 2008. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clinical Therapeutics 30(4): 587-604. (Pubitemid 351680489)
37. Jackson, M.B., and R.S. Ahima. 2006. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clinical Science 110: 143-152. (Pubitemid 43241476)
38. Berg, A.H., T.P. Combs, and P.E. Scherer. 2002. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism 13: 84-89. (Pubitemid 36740452)
39. Bouskila, M., U.B. Pajvani, and P.E. Scherer. 2005. Adiponectin: A relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? International Journal of Obesity and Related Metabolic Disorders 29(1): S17-S23. (Pubitemid 40343166)
40. Maeda, N., I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, and Y. Matsuzawa. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 8: 731-737. (Pubitemid 34778727)
41. Berg, A.H., T.P. Combs, X. Du, M. Brownlee, and P.E. Scherer. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7: 947-953. (Pubitemid 32756433)
42. Zwacka, T.P., V. Hornbach, and J. Torzewski. 2001. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 103: 1194-1197.
43. Gerszten, R.E., E.A. Garcia-Zepeda, Y.C. Lim, M. Yoshida, H.A. Ding, M.A. Gimbrone Jr., A.D. Luster, F.W. Luscinskas, and A. Rosenzweig. 1999. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398(6729): 718-723.
44. Charo, I.F., and M.B. Taubman. 2004. Chemokines in the pathogenesis of vascular disease. Circulation Research 95(9): 858-866. (Pubitemid 39435000)
45. Botti, C., C. Maione, G. Dogliotti, P. Russo, G. Signoriello, A.M. Molinari, M.M. Corsi, V. Sica, and G. Cobellis. 2012. Circulating cytokines present in the serum of peripheral arterial disease patients induce endothelial dysfunction. Journal of Biological Regulators and Homeostatic Agents 26(1): 67-79.
46. Tanaka, Y., D.H. Adams, S. Hubscher, H. Hirano, U. Siebenlist, and S. Shaw. 1993. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 361(6407): 79-82. (Pubitemid 23020778)
47. Schall, T.J., K. Bacon, R.D. Camp, J.W. Kaspari, and D.V. Goeddel. 1993. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. Journal of Experimental Medicine 177(6): 1821-1826.